As potential biomarkers for BLCA, both SPEF1 and SPEF2 require further investigation involving a larger cohort of BLCA patients to assess the expression of these proteins in body fluids, cytological samples, and tissue specimens. Here, SPEF2 is linked to bladder transitional cell carcinoma.